The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
Subscribe To Our Newsletter & Stay Updated
